Table 2.
Clinical data of 151 cancer-free subjects with lung tissue available for MethyLight assay.
| Never-smokers (n = 30) | Ever-smokers (n = 121) | |
|---|---|---|
| Age at surgery (mean years ± sd) | 43.7 ± 11.6 | 61.0 ± 9.9 |
| 20–39 | 11 (37%) | 2 (2%) |
| 40–49 | 8 (27%) | 14 (12%) |
| 50–59 | 9 (30%) | 33 (27%) |
| 60–69 | 2 (7%) | 43 (36%) |
| 70–79 | 0 (0%) | 29 (24%) |
|
| ||
| Female gender | 18 (60%) | 58 (48%) |
|
| ||
| Smoking pack years | ||
| 1–39 | N/A | 50 (41%) |
| ≥40 | N/A | 71 (59%) |
|
| ||
| Years since quitting a | ||
| 0 (Current) | N/A | 15 (13%) |
| 1–4 | N/A | 31 (26%) |
| 5–9 | N/A | 27 (23%) |
| 10–19 | N/A | 30 (25%) |
| ≥20 | N/A | 17 (14%) |
|
| ||
| Surgery | ||
| Lung volume reduction | 0 (0%) | 57 (47%) |
| Lung transplant | 9 (30%) | 31 (26%) |
| Wedge Biopsy | 18 (60%) | 24 (20%) |
| Lobectomy | 2 (7%) | 5 (4%) |
| Bullectomy | 0 (0%) | 4 (3%) |
| Segmentectomy | 1 (3%) | 0 (0%) |
|
| ||
| Number of samples evaluated | ||
| One sample | 17 (57%) | 23 (19%) |
| Multiple samples | 13 (43%) | 98 (81%) |
|
| ||
| Sample locations b | ||
| Upper lobe only | 5 (17%) | 60 (50%) |
| Middle lobe or lingula only | 6 (21%) | 1 (1%) |
| Lower lobe only | 10 (34%) | 21 (18%) |
| Multiple lobes | 8 (28%) | 37 (31%) |
|
| ||
| Etiology | ||
| Emphysemac | 3 (10%) | 86 (71%) |
| Inflammatory conditionsd | 13 (43%) | 21 (17%) |
| Infectious diseases | 4 (13%) | 7 (6%) |
| Cystic fibrosis | 5 (17%) | 0 (0%) |
| Pulmonary hypertension | 1 (3%) | 2 (2%) |
| Sarcoidosis | 1 (3%) | 1 (1%) |
| Lymphoid hyperplasia | 1 (3%) | 1 (1%) |
| Infarct | 1 (3%) | 1 (1%) |
| Hemangioma | 0 (0%) | 1 (1%) |
| Trapped lung | 1 (3%) | 0 (0%) |
| No histologic abnormalities | 0 (0%) | 1 (1%) |
aQuit years not available for 1 subject.
bSample location unknown for 4 samples from 3 subjects.
cSee results section for details.
dInflammatory conditions included chronic bronchitis, bronchiectasis, pulmonary fibrosis, and granulomatous disease.